Exhibit 1.

Characteristics Of Forty-Seven Oral Oncologics Available In The US Market, First Quarter 2006 Through Third Quarter 2011

Category	Oncologics
	Number	Percent
THERAPEUTIC CLASS
Alkylating agentsa	9	19
Topoisomerase inhibitorsb	2	4
Antimetabolitesc	5	11
Hormonal agentsd	12	26
Targeted agentse	14	32
Other	6	131
PATENT PROTECTION STATUS DURING STUDY PERIOD
Patent protected throughout	22	47
Lost patent protection	5	11
Generic throughout	20	43
FEE-FOR-SERVICE MEDICARE OUTPATIENT COVERAGE
Medical benefit (Part B)	9	19
Pharmacy benefit (Part D)	38	81

SOURCE Authors’ analysis of data from IMS Health’s National Sales Perspectives and the Food and Drug Administration’s approved drug labels.

^aAgents that cause the replacement of hydrogen by an alkyl group, especially in a biologically important molecule. These agents have mutagenic activity to inhibit cell division and growth.

^bAgents that block the ligation step of the cell cycle, generating single- and double-stranded breaks that harm the integrity of the genome. Introduction of these breaks leads to apoptosis and cell death.

^cAgents used to interfere with DNA production and therefore cell division and the growth of tumors. Because cancer cells spend more time dividing than other cells, inhibiting cell division harms cancer cells more than other cells.

^dAgents that manipulate the endocrine system by adding exogenous-specific hormones, particularly steroid hormones, or by inhibiting the production or activity of such hormones (hormone antagonists). Because steroid hormones are powerful drivers of gene expression in certain cancer cells, changing the levels or activity of certain hormones can cause certain cancers to cease growing or undergo cell death.

^eIncludes agents that target specific genetic pathways, interrupting normal cell functioning such as cell division.